Xona already holds the exclusive license to manufacture its neuronal research devices in the US, and this new European patent adds to its exclusivity in Europe, specifically the United Kingdom, Ireland, Switzerland, France, Spain and Germany.
The patents are assigned to the University of California and licensed exclusively to Xona.
Dr. Anne Taylor, Assistant Professor at the University of North Carolina at Chapel Hill, invented the neuron device while working as a graduate student in the laboratory of Dr. Noo Li Jeon at the University of California, Irvine in 2003. Dr. Carl Cotman, Professor of Neuroscience at the University of California, Irvine, helped guide Dr. Taylor's research.
Dr. Taylor, Dr. Jeon and Dr. Cotman are all credited as co-inventors.
Xona Microfluidics is focused on manufacturing and distributing microfluidic devices to neuroscientists and laboratories worldwide. The company has offices in Temecula, California and Research Triangle Park in Durham, North Carolina.
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Samsung Biologics collaborates with Lilly for new Gateway Labs site in Korea
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio